A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 278 participants.
Also called NCT03361501
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 278 participants
- Sponsor
- Registry
-
NCT03361501
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Mexico
- Registry status
- Completed
Technical summary
Registry record NCT03361501. Randomized; double masking; primary purpose treatment. Start 2018-02-01 (actual); primary completion 2019-09-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)
- Acronym
- TRILOGY 2
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- CaPre
- Intervention (Drug)
- Placebo
- Lead sponsor
- Grace Therapeutics Inc.
Record details
- Record id
cardio:ct-nct03361501- Content hash
34b4200e24232b45007f4147d2613d13b9c1b43dccf4a40a816adb1820ba4473